NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lung cancer: drug duo targets KRAS mutation
Disease control Not yet recruitingThis study tests two experimental drugs, Glecirasib and Ivonescimab, together as a first treatment for people with a specific type of advanced lung cancer (KRAS G12C mutation, PD-L1 positive). The goal is to see if the combination is safe and can shrink tumors. About 42 adults wi…
Matched conditions: NSCLC STAGE IV
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
Lung cancer drug dose doubled for stubborn tumors in new trial
Disease control Not yet recruitingThis study tests whether a higher dose (160 mg) of the targeted drug firmonertinib can shrink or control advanced EGFR-mutant lung cancer in people whose tumors stayed stable after 8 weeks on the standard 80 mg dose. About 28 adults with stage IV non-small cell lung cancer and no…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 17, 2026 02:05 UTC